Holohemispheric Invasive Aspergillus Granulomatous Cerebritis of the Brain

Kulanthaivelu, Karthik; Prasad, Chandrajit; Reddy, Yerasi Varun; Mahadevan, Anita

doi:10.1016/j.wneu.2019.09.100

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the patients (a known case of wegener granulomatosis) was cured with AMB (29 days) + ICZ (410 days), another individual (suffering from laryngeal cancer) receiving AMB (25 days) + ICZ (13 days) died, and the last one (a case of systemic lupus erythematosus and end‐stage renal disease) was cured by receiving liposomal AMB (44 days) + VCZ and ITZ (380 days) 10 . Taking into consideration that outcomes of monotherapy vs. combination therapy could be an important point of comparison in previous reports of neuroaspergillosis, Karthic et al reported an expired case that was treated with VCZ, 11 Haroon and colleagues mentioned another expired case who received AMB, 12 but the overall results of combination therapy were more promising; Gruter et al reported a neuroaspergillosis patient (who also had thyroid cancer) receiving VCZ+ AMB+ ISZ who was cured 5 . Leroy et al 13 and Turki et al 14 both reported cured cases of neuroaspergillosis treated with VCZ + liposomal AMB, and of 5 cases described in Tattevin and colleagues' study, 3 were cured by combination therapy 10 …”

Section: Discussionmentioning

confidence: 99%

Promising effects of corticosteroid treatment in combination with antifungal agents in a patient with Aspergillus meningitis

Jalali

Lotfali

Rezaei

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

About 10%-15% of cases of Invasive Aspergillosis (IA) affect the central nervous system (CNS) as neuroaspergillosis. 1 Being immunocompromised is the major risk factor for IA of the CNS with reported mortality rate of approximately 90% (compared with 10%-20% in immunocompetent individuals); and developing a proper medical approach for the treatment of neuroaspergillosis is very challenging because of its poor response to treatment. 2 This could be due to intrinsic or acquired antifungal resistance, which is an emerging problem in current era, and even with current guideline of using new antifungal agents, outcomes of patients with this condition are not promising. 3 Patients with neuroaspergillosis present with a variety of signs and symptoms such as fever, headache, dizziness, seizure, lethargy, altered mental status, gait disorders, visual impairment, and diplopia. 4 One of the main manifestations of previously reported cases of IA involving the CNS is mass lesions seen in infectious meningitis. 5

show abstract